App-Quantinova.ai

Capmatinib vs docetaxel as second- or third-line therapy in patients with locally advanced or metastatic METex14-mutated NSCLC: The GeoMETry-III trial

Pierre Jean Souquet - American Association for Cancer Research (AACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Brain metastasis

Docetaxel

Prostate cancer targeting therapy using PSA promoter-driven perforin expression vector encapsulated in liposomes conjugated with anti-PSMA antibody

Kosuke Mizutani - American Association for Cancer Research (AACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Prostate cancer

Docetaxel

Non small cell lung cancer: options and outcome of treatment beyond second line

Tamás Erdélyi - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Docetaxel

Temporal Effects of Docetaxel on Vertebral Bone Metastasis in Athymic Nude Rats

Mohammedayaz Rangrez - Canadian Orthopaedic Association (COA|CORA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Bone metastases

Docetaxel

Long-term outcomes in EV-301 24-month findings from the phase 3 trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma.

Jonathan E. Rosenberg - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2022

Therapeutic Area

Disease

Drug/Treatment

Urology

Advanced Urothelial Carcinoma

Docetaxel

A phase III randomized trial of eribulin (E) with or without gemcitabine versus standard of care (SOC) for metastatic urothelial carcinoma (UC) refractory to or ineligible for PD/PDL1 antibody (Ab) SWOG S1937.

Sarmad Sadeghi - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2022

Therapeutic Area

Disease

Drug/Treatment

Urology

Advanced Urothelial Carcinoma

Docetaxel

TheraP 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel—Overall survival after median follow-up of 3 years (ANZUP 1603).

Michael S Hofman - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2022

Therapeutic Area

Disease

Drug/Treatment

Urology

Metastatic castration-resistant prostate cancer

Docetaxel

A phase 1/2 multicenter investigator-initiated trial of DKN-01 as monotherapy or in combination with docetaxel for the treatment of metastatic castration-resistant prostate cancer (mCRPC).

David R Wise - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2022

Therapeutic Area

Disease

Drug/Treatment

Urology

Metastatic castration-resistant prostate cancer

Docetaxel

A pilot trial of neoantigen DNA vaccine in combination with nivolumab/ipilimumab and prostvac in metastatic hormone-sensitive prostate cancer (mHSPC).

Koral Shah - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2022

Therapeutic Area

Disease

Drug/Treatment

Urology

Prostate cancer

Docetaxel

Association of prostate-specific antigen (PSA) response and overall survival (OS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) from the phase 3 ARASENS trial.

Fred Saad - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2022

Therapeutic Area

Disease

Drug/Treatment

Urology

Prostate cancer

Docetaxel

A phase 2, multicenter, parallel-group, open-label study of vudalimab (XmAb20717), a PD-1 x CTLA-4 bispecific antibody, alone or in combination with chemotherapy or targeted therapy in patients with molecularly defined subtypes of metastatic castration-resistant prostate cancer.

Mark N. Stein - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2022

Therapeutic Area

Disease

Drug/Treatment

Urology

Metastatic castration-resistant prostate cancer

Docetaxel

Alliance A031902 (CASPAR) A randomized, phase (ph) 3 trial of enzalutamide with rucaparib/placebo in first-line metastatic castration-resistant prostate cancer (mCRPC).

Arpit Rao - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2022

Therapeutic Area

Disease

Drug/Treatment

Urology

Metastatic castration-resistant prostate cancer

Docetaxel

CCTG PR21 A randomized phase II study of [177lu]lu-PSMA-617 verus docetaxel in patients with metastatic castration-resistant prostate cancer and PSMA-positive disease (NCT04663997).

Kim N. Chi - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2022

Therapeutic Area

Disease

Drug/Treatment

Urology

Metastatic castration-resistant prostate cancer

Docetaxel

Assessing intermediate clinical endpoints (ICE) as potential surrogates for overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC).

Susan Halabi - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2022

Therapeutic Area

Disease

Drug/Treatment

Urology

Prostate cancer

Docetaxel

A phase 2 randomized study of oral docetaxel plus ritonavir (ModraDoc006/r) in patients with metastatic castration-resistant prostate cancer (mCRPC).

Ulka N. Vaishampayan - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2022

Therapeutic Area

Disease

Drug/Treatment

Urology

Metastatic castration-resistant prostate cancer

Docetaxel

Clinical outcomes and safety of enzalutamide (ENZA) plus androgen-deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC) in patients aged < 75 and ≥ 75 years ARCHES post hoc analysis.

Russell Zelig Szmulewitz - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2022

Therapeutic Area

Disease

Drug/Treatment

Urology

Prostate cancer

Docetaxel

Effect of docetaxel (D) use on survival outcomes in patients with metastatic castration-sensitive prostate cancer (mCSPC) treated with novel hormonal therapies (NHTs) A meta-analysis.

Deniz Can Guven - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2022

Therapeutic Area

Disease

Drug/Treatment

Urology

Prostate cancer

Docetaxel

Eight-year survival rates by baseline prognostic groups in patients with metastatic hormone-sensitive prostate cancer (mHSPC) An analysis from the ECOG-ACRIN 3805 (CHAARTED) trial.

Abhishek Tripathi - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2022

Therapeutic Area

Disease

Drug/Treatment

Urology

Prostate cancer

Docetaxel

Indirect comparisons of triplet therapy as compared to novel hormonal therapy doublets in patients with metastatic castration sensitive prostate cancer.

Syed Arsalan Ahmed Naqvi - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2022

Therapeutic Area

Disease

Drug/Treatment

Urology

Prostate cancer

Docetaxel

Real-world treatment patterns in the U.S. and trends pre-post CARD trial among patients with metastatic castration-resistant prostate cancer.

Shashank Ghantoji - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2022

Therapeutic Area

Disease

Drug/Treatment

Urology

Metastatic castration-resistant prostate cancer

Docetaxel

Filters

2459 Abstracts